MP46-17 HEALTH-RELATED QUALITY OF LIFE AND TREATMENT-RELATED SIDE-EFFECTS IN PATIENTS WHO HAVE BEEN IN REMISSION FROM TESTICULAR CANCER FOR 12-24 MONTHS. (May 2022)